Get the Stockscreener App
53.53
0.80%
-0.3926
Protagonist Therapeutics Inc stock is traded at $53.53, with a volume of 207.85K.
It is down -0.80% in the last 24 hours and up +14.76% over the past month.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
See More
Previous Close:
$53.92
Open:
$54
24h Volume:
207.85K
Relative Volume:
0.20
Market Cap:
$3.49B
Revenue:
$45.48M
Net Income/Loss:
$169.95M
P/E Ratio:
20.43
EPS:
2.62
Net Cash Flow:
$230.85M
1W Performance:
-5.11%
1M Performance:
+14.76%
6M Performance:
+28.92%
1Y Performance:
+70.19%
1-Day Range:
$52.79
$54.97
1-Week Range:
$52.79
$57.03
52-Week Range:
$30.67
$60.60
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Name
Protagonist Therapeutics Inc
Sector
Industry
Phone
(510) 474-0170
Address
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
53.52 | 3.49B | 45.48M | 169.95M | 230.85M | 2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.22 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
510.11 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
310.63 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.37 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
247.76 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-06-24 | Initiated | Goldman | Neutral |
| Nov-05-24 | Initiated | Wedbush | Outperform |
| Sep-24-24 | Initiated | TD Cowen | Buy |
| Sep-09-24 | Initiated | Truist | Buy |
| Oct-30-23 | Initiated | CapitalOne | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Aug-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Feb-11-22 | Initiated | BTIG Research | Buy |
| Oct-12-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-11-21 | Upgrade | Northland Capital | Market Perform → Outperform |
| Sep-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-24-21 | Initiated | JMP Securities | Mkt Outperform |
| May-24-21 | Initiated | Northland Capital | Outperform |
| Jan-06-21 | Initiated | JP Morgan | Overweight |
| Dec-16-20 | Initiated | Piper Sandler | Overweight |
| Sep-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-15-20 | Initiated | Jefferies | Buy |
| May-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| May-09-19 | Upgrade | Stifel | Hold → Buy |
| Dec-06-18 | Initiated | Nomura | Buy |
| Jan-29-18 | Initiated | Stifel | Buy |
| Jul-21-17 | Initiated | BTIG Research | Buy |
View All
Protagonist Therapeutics Inc Stock (PTGX) Latest News
10 Biotech Stocks Screaming a Buy - Insider Monkey
Protagonist Therapeutics’ SWOT analysis: biotech stock poised for growth By Investing.com - Investing.com South Africa
Protagonist Therapeutics’ SWOT analysis: biotech stock poised for growth - Investing.com
BIOTECHNOLOGY VALUE FUND L P's Strategic Acquisition in Protagonist Therapeutics Inc - GuruFocus
Citigroup Initiates Coverage on Protagonist Therapeutics (PTGX) with a 'Buy' Rating | PTGX Stock News - GuruFocus
Protagonist Therapeutics (PTGX) Initiated at Buy by Citi with $7 - GuruFocus
Citigroup Initiates Protagonist Therapeutics at Buy With $72 Price Target - MarketScreener
Protagonist Therapeutics (PTGX) Initiated at Buy by Citi with $72 Target | PTGX Stock News - GuruFocus
How To Trade (PTGX) - news.stocktradersdaily.com
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Rating of "Buy" by Analysts - MarketBeat
GAMMA Investing LLC Raises Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Insider Sells $570,300.00 in Stock - MarketBeat
Protagonist Therapeutics’ SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com Canada
Protagonist Therapeutics’ SWOT analysis: promising pipeline drives stock outlook - Investing.com
Subdued Growth No Barrier To Protagonist Therapeutics, Inc. (NASDAQ:PTGX) With Shares Advancing 27% - simplywall.st
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025 - The Columbus Dispatch
Protagonist Therapeutics (NASDAQ:PTGX) Rating Increased to Hold at Wall Street Zen - MarketBeat
Hennion & Walsh Asset Management Inc. Has $1.26 Million Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
California State Teachers Retirement System Sells 316 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics (NASDAQ:PTGX) Upgraded to “Hold” at Wall Street Zen - Defense World
Protagonist Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:PTGX - Benzinga
Exploring Three High Growth Tech Stocks In The US Market - Yahoo Finance
(PTGX) Long Term Investment Analysis - news.stocktradersdaily.com
Protagonist Therapeutics (NASDAQ:PTGX) Cut to "Sell" at Wall Street Zen - MarketBeat
Protagonist Therapeutics’ (PTGX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Protagonist-Takeda, Novartis post phase III wins - BioWorld MedTech
H.C. Wainwright reaffirms Buy rating on Protagonist Therapeutics stock By Investing.com - Investing.com UK
BTIG maintains buy rating on Protagonist Therapeutics stock By Investing.com - Investing.com UK
Protagonist Therapeutics (PTGX) Rating and Price Target Reaffirmed | PTGX Stock News - GuruFocus
Protagonist Therapeutics: Promising Future with Rusfertide as a Standard of Care for Polycythemia Vera - TipRanks
ASCO 2025: Protagonist-Takeda, Novartis post phase III wins - BioWorld MedTech
Transcript : Protagonist Therapeutics, Inc.Special Call - marketscreener.com
Protagonist Therapeutics, Inc. and Takeda Announce Asco Plenary Presentation Highlighting Full 32-Week Results from Phase 3 Verify Study of Rusfertide - marketscreener.com
Protagonist Therapeutics, Takeda's Potential Polycythemia Vera Drug Meets Primary Endpoint - marketscreener.com
Protagonist Therapeutics (PTGX): Promising Phase 3 Results for R - GuruFocus
Protagonist Therapeutics (PTGX): Promising Phase 3 Results for Rusfertide | PTGX Stock News - GuruFocus
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera - Quantisnow
Protagonist Therapeutics (NASDAQ:PTGX) Downgraded to Sell Rating by Wall Street Zen - Defense World
Cache Advisors LLC Makes New $392,000 Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics (PTGX) Rose on Positive Trial Outcome - MSN
D. E. Shaw & Co. Inc. Sells 21,121 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Bank of America Corp DE Has $5.21 Million Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics’ SWOT analysis: stock poised for growth amid clinical advancements - Investing.com India
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Position Reduced by Ameriprise Financial Inc. - Defense World
Protagonist Therapeutics' (PTGX) Buy Rating Reiterated at HC Wainwright - MarketBeat
BNP Paribas Financial Markets Has $751,000 Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics earnings missed by $0.13, revenue fell short of estimates - Investing.com Canada
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025 | PTGX Stock News - GuruFocus
Exclusive: Protagonist Therapeutics CEO Reveals Company Strategy at Major Jefferies Healthcare Conference - Stock Titan
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Rating of “Buy” from Analysts - Defense World
Protagonist Therapeutics (NASDAQ:PTGX) Given “Buy” Rating at HC Wainwright - Defense World
Protagonist Therapeutics Inc Stock (PTGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Protagonist Therapeutics Inc Stock (PTGX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MOLINA ARTURO MD | Chief Medical Officer |
Jun 10 '25 |
Option Exercise |
8.04 |
10,000 |
80,400 |
93,892 |
| MOLINA ARTURO MD | Chief Medical Officer |
Jun 10 '25 |
Sale |
57.03 |
10,000 |
570,300 |
83,892 |
| MOLINA ARTURO MD | Chief Medical Officer |
Jun 09 '25 |
Sale |
55.51 |
10,000 |
555,100 |
83,892 |
0.79%
0.99%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):